LY-334370

LY-334370
Clinical data
Other names	LY334370; LY-334,370
Drug class	Serotonin 5-HT1F receptor agonist
ATC code	None;
Identifiers
	IUPAC name 4-fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide;
CAS Number	182563-08-2;
PubChem CID	5311258;
IUPHAR/BPS	20; 151;
ChemSpider	4470773;
UNII	5Q7I1WL2UY;
ChEMBL	ChEMBL101690;
CompTox Dashboard (EPA)	DTXSID40415518 ;
Chemical and physical data
Formula	C21H22FN3O
Molar mass	351.425 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)NC(=O)C4=CC=C(C=C4)F;
	InChI InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26); Key:MDMJLMDBRQXOOI-UHFFFAOYSA-N;

LY-334370 is a selective serotonin 5-HT_1F receptor agonist^[1] of the triptan and piperidinylindole families which was under development by Eli Lilly and Company for the treatment of migraine headaches.^[2] The drug showed efficacy in a phase II clinical trial^[3] but further development was halted due to toxicity detected in animals.^[4] It is closely related to tryptamines like the psychedelic drug dimethyltryptamine (DMT), but is not technically a tryptamine itself and is instead a piperidinylindole similarly to naratriptan.^[5] The drug's affinities for various serotonin receptors have been reported.^[6]